The Influence of Various Parameters on the Success of Sensor-Controlled Scalp Cooling in Preventing Chemotherapy-Induced XXXX .

@entity1665 @entity1 @entity137 @entity0 @entity5 @entity1239 @entity786 @entity1311 @entity13010
BACKGROUND: The influence of systemic comorbidities on the success of scalp cooling during chemotherapy (CT) is widely unexplored. Comorbidities often require additional medication which itself can occasionally cause @entity1665 . This study investigates the influence of selected parameters on the efficacy of scalp cooling for the prevention of CT-induced @entity1665 . @entity1 AND METHODS: 226 @entity5 @entity1 were treated with various CT regimens in combination with sensor-controlled scalp cooling. 136 @entity0 @entity1 received (neo)adjuvant therapy, and 76 of these @entity1 received @entity13010 and @entity786 (4* EC 3w) followed by @entity1311 (12* T w). The following parameters were prospectively investigated: chemotherapy-induced @entity1665 , systemic comorbidities and co-medication, @entity1239 abuse, hair treatment, menopausal status, and trichologic status. RESULTS: Scalp cooling was successful (no or not visible hair loss; common @entity137 criteria 0-1) in 65% of all @entity1 , in 65% of the 136 @entity0 @entity1 , and in 68% of the 76 @entity1 receiving EC/T. In this subgroup, premenopausal @entity1 (p = 0.009) and those without systemic comorbidities (p = 0.003), without co-medication (p < 0.001) and with high hair density (p = 0.038) showed less hair loss during CT; an effect was also seen for @entity1239 abuse (p = 0.023). Hair length and hair treatment had no significant influence. CONCLUSION: Sensor-controlled scalp cooling represents an effective addition to supportive @entity5 therapy. The success of scalp cooling depends on the applied CT regimen. Parameters like menopausal status, systemic comorbidities, medication, @entity1239 abuse, and original hair density also influence the outcome of hair loss prevention.
